Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 4Phase 1 4

Status

Terminated 3Unknown 2Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Myeloid 1Classical hematology 1

Conditions

Stomach Neoplasms 2Myeloproliferative Disorders 1Dermoid Cyst 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anemia 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Interventional × vactosertib × Clear all
NCT03844750 2025-12-31

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

University of California, San Francisco

Phase 2 Terminated
6 enrolled 12 charts
Gastrointestinal

Colorectal Neoplasms

NCT04103645 2025-07-02

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

Weill Medical College of Cornell University

Phase 2 Terminated
2 enrolled 12 charts
Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders

NCT04515979 2024-12-09

Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

MedPacto, Inc.

Phase 2 Terminated
11 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06219733 2024-12-09

MP-VAC-206

MedPacto, Inc.

Phase 2 Withdrawn

Dermoid Cyst

NCT04893252 2022-11-30

Vactosertib and Durvalumab in Gastric Cancer

National Cancer Center, Korea

Phase 2 Unknown
55 enrolled
Gastrointestinal

Stomach Neoplasms

NCT04656002 2022-06-15

As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Samsung Medical Center

Phase 2 Unknown
43 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡